日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD

对于新诊断的费城染色体阴性B细胞前体急性淋巴细胞白血病,采用减量化疗后序贯blinatumomab治疗:与高剂量CVAD方案的倾向性匹配比较

Lu, Jing; Zhu, Yu; Qiu, Huiying; Wang, Ying; Zhou, Xin; Dai, Haiping; Lu, Xuzhang; Gu, Bin; Hong, Ming; Miao, Miao; Lu, Ruinan; Wang, Jun; Wu, Qian; Xue, Mengxing; Wang, Yun; Deng, Ailing; Shen, Yaoyao; Liu, Yin; Dou, Xueqing; Lei, Yutian; Yang, Xiaofei; Chen, Suning

Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial

降低剂量化疗联合blinatumomab作为新诊断的Ph阴性B细胞前体急性淋巴细胞白血病诱导治疗:一项II期试验

Lu, Jing; Qiu, Huiying; Wang, Ying; Zhou, Xin; Dai, Haiping; Lu, Xuzhang; Yang, Xiaofei; Gu, Bin; Hong, Ming; Miao, Miao; Lu, Ruinan; Wang, Jun; Wu, Qian; Xue, Mengxing; Wang, Yun; Deng, Ailing; Shen, Yaoyao; Liu, Yin; Dou, Xueqing; Lei, Yutian; Wu, Depei; Zhu, Yu; Chen, Suning

Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.

血浆中 S100A8/A9、组蛋白/DNA 复合物和游离 DNA 的水平可预测免疫性血栓性血小板减少性紫癜的不良后果

Sui Jingrui, Lu Ruinan, Halkidis Konstantine, Kocher Nicole K, Cao Wenjing, Marques Marisa B, Zheng X Long

Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura

血浆中 Syndecan-1 和可溶性血栓调节蛋白水平升高可预测血栓性血小板减少性紫癜的不良预后

Lu, Ruinan; Sui, Jingrui; Zheng, X Long

Modelling the spatial dynamics of plasmid transfer and persistence

质粒转移和持久性的空间动态建模

Krone, Stephen M; Lu, Ruinan; Fox, Randal; Suzuki, Haruo; Top, Eva M